Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
© 2022 The Author(s)..
BACKGROUND: Immunocompromised individuals are highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Whether vaccine-induced immunity in these individuals involves oral cavity, a primary site of infection, is presently unknown.
METHODS: Immunocompromised patients (n = 404) and healthy controls (n = 82) participated in a prospective clinical trial (NCT04780659) encompassing two doses of the mRNA BNT162b2 vaccine. Primary immunodeficiency (PID), secondary immunodeficiencies caused by human immunodeficiency virus (HIV) infection, allogeneic hematopoietic stem cell transplantation (HSCT)/chimeric antigen receptor T cell therapy (CAR-T), solid organ transplantation (SOT), and chronic lymphocytic leukemia (CLL) patients were included. Salivary and serum immunoglobulin G (IgG) reactivities to SARS-CoV-2 spike were measured by multiplex bead-based assays and Elecsys anti-SARS-CoV-2 S assay.
FINDINGS: IgG responses to SARS-CoV-2 spike antigens in saliva in HIV and HSCT/CAR-T groups were comparable to those of healthy controls after vaccination. The PID, SOT, and CLL patients had weaker responses, influenced mainly by disease parameters or immunosuppressants. Salivary responses correlated remarkably well with specific IgG titers and the neutralizing capacity in serum. Receiver operating characteristic curve analysis for the predictive power of salivary IgG yielded area under the curve (AUC) = 0.95 and positive predictive value (PPV) = 90.7% for the entire cohort after vaccination.
CONCLUSIONS: Saliva conveys vaccine responses induced by mRNA BNT162b2. The predictive power of salivary spike IgG makes it highly suitable for screening vulnerable groups for revaccination.
FUNDING: Knut and Alice Wallenberg Foundation, Erling Perssons family foundation, Region Stockholm, Swedish Research Council, Karolinska Institutet, Swedish Blood Cancer Foundation, PID patient organization of Sweden, Nordstjernan AB, Center for Medical Innovation (CIMED), Swedish Medical Research Council, and Stockholm County Council (ALF).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Med (New York, N.Y.) - 3(2022), 2 vom: 11. Feb., Seite 137-153.e3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Healy, Katie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.05.2022 Date Revised 05.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT04780659 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medj.2022.01.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336099495 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336099495 | ||
| 003 | DE-627 | ||
| 005 | 20231225231351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medj.2022.01.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336099495 | ||
| 035 | |a (NLM)35075450 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Healy, Katie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2022 | ||
| 500 | |a Date Revised 05.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04780659 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a BACKGROUND: Immunocompromised individuals are highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Whether vaccine-induced immunity in these individuals involves oral cavity, a primary site of infection, is presently unknown | ||
| 520 | |a METHODS: Immunocompromised patients (n = 404) and healthy controls (n = 82) participated in a prospective clinical trial (NCT04780659) encompassing two doses of the mRNA BNT162b2 vaccine. Primary immunodeficiency (PID), secondary immunodeficiencies caused by human immunodeficiency virus (HIV) infection, allogeneic hematopoietic stem cell transplantation (HSCT)/chimeric antigen receptor T cell therapy (CAR-T), solid organ transplantation (SOT), and chronic lymphocytic leukemia (CLL) patients were included. Salivary and serum immunoglobulin G (IgG) reactivities to SARS-CoV-2 spike were measured by multiplex bead-based assays and Elecsys anti-SARS-CoV-2 S assay | ||
| 520 | |a FINDINGS: IgG responses to SARS-CoV-2 spike antigens in saliva in HIV and HSCT/CAR-T groups were comparable to those of healthy controls after vaccination. The PID, SOT, and CLL patients had weaker responses, influenced mainly by disease parameters or immunosuppressants. Salivary responses correlated remarkably well with specific IgG titers and the neutralizing capacity in serum. Receiver operating characteristic curve analysis for the predictive power of salivary IgG yielded area under the curve (AUC) = 0.95 and positive predictive value (PPV) = 90.7% for the entire cohort after vaccination | ||
| 520 | |a CONCLUSIONS: Saliva conveys vaccine responses induced by mRNA BNT162b2. The predictive power of salivary spike IgG makes it highly suitable for screening vulnerable groups for revaccination | ||
| 520 | |a FUNDING: Knut and Alice Wallenberg Foundation, Erling Perssons family foundation, Region Stockholm, Swedish Research Council, Karolinska Institutet, Swedish Blood Cancer Foundation, PID patient organization of Sweden, Nordstjernan AB, Center for Medical Innovation (CIMED), Swedish Medical Research Council, and Stockholm County Council (ALF) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a immunodeficiency | |
| 650 | 4 | |a saliva | |
| 650 | 4 | |a serum | |
| 650 | 4 | |a transplantation | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin A, Secretory |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Pin, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Puran |e verfasserin |4 aut | |
| 700 | 1 | |a Söderdahl, Gunnar |e verfasserin |4 aut | |
| 700 | 1 | |a Nowak, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Mielke, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Hansson, Lotta |e verfasserin |4 aut | |
| 700 | 1 | |a Bergman, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, C I Edvard |e verfasserin |4 aut | |
| 700 | 1 | |a Ljungman, Per |e verfasserin |4 aut | |
| 700 | 1 | |a Valentini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Blennow, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Österborg, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Gabarrini, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Manei, Khaled |e verfasserin |4 aut | |
| 700 | 1 | |a Alkharaan, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Sobkowiak, Michał Jacek |e verfasserin |4 aut | |
| 700 | 1 | |a Yousef, Jamil |e verfasserin |4 aut | |
| 700 | 1 | |a Mravinacova, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Cuapio, Angelica |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xinling |e verfasserin |4 aut | |
| 700 | 1 | |a Akber, Mira |e verfasserin |4 aut | |
| 700 | 1 | |a Loré, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Hellström, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Muschiol, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bogdanovic, Gordana |e verfasserin |4 aut | |
| 700 | 1 | |a Buggert, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Ljunggren, Hans-Gustaf |e verfasserin |4 aut | |
| 700 | 1 | |a Hober, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsson, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Aleman, Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Sällberg Chen, Margaret |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Med (New York, N.Y.) |d 2020 |g 3(2022), 2 vom: 11. Feb., Seite 137-153.e3 |w (DE-627)NLM314117954 |x 2666-6340 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:2 |g day:11 |g month:02 |g pages:137-153.e3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medj.2022.01.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 2 |b 11 |c 02 |h 137-153.e3 | ||